Oncolytics Biotech Inc. (ONCY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncolytics Biotech Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.027 -- 00:00:06.793 Good afternoon, and welcome to OnClinic's Biotech's first quarter conference call. 00:00:06.793 -- 00:00:09.155 All participants are now in listen-only mode. 00:00:09.155 -- 00:00:13.340 There will be a question and answer session at the end of this call. 00:00:13.340 -- 00:00:17.484 Please be advised that this call is being recorded at the company's request. 00:00:17.484 -- 00:00:21.388 I would now like to turn the call over to Jan Patton, Director of Investor Relations 00:00:21.388 -- 00:00:23.530 and Communication. Please go ahead. 00:00:23.530 -- 00:00:28.596 Thank you, Operator. Today, we'll provide an update on the quarter and 00:00:28.596 -- 00:00:33.210 a review of our financials. As a reminder, various remarks made during this call contain 00:00:33.210 -- 00:00:36.815 certain forward-looking statements relating to the company's business prospects and the 00:00:36.815 -- 00:00:40.820 development and commercialization of Pella Rear Rep, including statements regarding the 00:00:40.820 -- 00:00:45.766 company's ongoing CEO search, our mission, strategies, and milestones, the company's 00:00:45.766 -- 00:00:50.492 belief as to the potential and mechanism of action of Pella Rear Rep as a cancer therapeutic, 00:00:50.492 -- 00:00:54.877 our potential registrational opportunities for Pella Rear Rep, and our plans and strategies 00:00:54.877 -- 00:01:00.072 related thereto, our plans to continue enrollment in Goblet Cohort 5, our ongoing 00:01:00.072 -- 00:01:04.096 business development initiatives, and other statements related to anticipated developments 00:01:04.096 -- 00:01:08.240 in the company's business. These statements are based on management's current expectations 00:01:08.240 -- 00:01:11.984 and beliefs and are subject to...